20 μg dose of SYS6006
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions
SARS-CoV-2
Phase 1
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.
NCT05354063
Start: 2022-06-01End: 2023-10-01Target: 40Updated: 2023-05-24
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
NCT05354089
Start: 2022-04-27End: 2023-10-01Target: 40Updated: 2023-05-24